Cinclus Pharma and Implantica, a duo of Swedish companies, are working to create new therapies for gastroesophageal reflux disease (GERD) but are approaching the problem from opposite ends of the health care spectrum.
Implantica has developed RefluxStop, a CE-marked implant designed to transform the anatomical features associated with GERD.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?